S ince the seminal publications from the Framingham study in the mid-60s, 1 the measurement of lipid levels, mainly of total cholesterol, total triglycerides, and low-density lipoprotein and high-density lipoprotein cholesterol, is routine clinical practice for cardiovascular disease (CVD) and lipid-lowering therapy. A more detailed assessment of the lipid composition, that is, the molecular species that constitute the lipid classes, is not widely used, mainly because of the caveats of assessing the lipidome. The human lipidome is estimated to include thousands of molecular lipid species with functional diversity. The molecular lipid species within a lipid class share a modular composition with fatty acids being attached to a common backbone. Although a characteristic head group within the backbone defines the lipid class, the diversity of molecular lipid species derives from the conjugated fatty acids. 2 The conjugated fatty acids can differ in their carbon chain length, the number, position, and configuration (cis or trans) of their double bonds, and the position and type (acyl, alkyl, or vinyl) of linkage to the backbone.
enhances accuracy of analyte identification and quantitation in comparison with untargeted MS analysis without authentic standards. 7 Because of economic considerations and lack of availability, a limited set of standards is commonly used, and relative quantitation is achieved by linear extrapolation through response factors. 6 This issue of Circulation features 2 studies that break new ground in relating lipid species to cardiometabolic outcomes.
Alshehry and coworkers 8 investigated 310 lipid species within 22 lipid classes in almost 4000 subjects with diabetes mellitus and found a signature of 42 lipid species associated with incident CVD, cardiovascular death, or both. The lipid signature determined by using targeted liquid chromatography-electrospray ionization-tandem MS was dominated by glycerophospholipids and sphingolipids. Addition of select lipid species to conventional risk factors entailed moderate improvements in CVD risk prediction, and replication in independent patient samples was in part successful. Lipids included in the cardiovascular events Alshehry and colleagues integrated their findings for PCs and phosphatidylethanolamines with underlying enzymatic pathways. 8 Only by considering lipid species in the context of their metabolism can new mechanistic knowledge be generated.
Syme and coworkers, 9 using targeted liquid chromatograph-electrospray ionization-MS, report the first lipidomic study conducted in adolescents. In almost 1000 participants, they measured 69 PCs, ie, members of the glycerophospholipid class, of which 21 were associated with at least 1 CVD risk factor out of visceral adiposity, blood pressure, insulin resistance, and atherogenic dyslipidemia. PC(16:0/2:0), a platelet-activating factor possessing a 2-carbon acetyl at its sn-2 position, and PC(14:1/0:0), a lysophosphatidylcholine possessing only 1 fatty acid of 14 carbon atoms, showed the strongest inverse and direct associations with CVD risk factors, respectively. The findings by Syme and colleagues point toward the detrimental effects of CVD risk factors on biologically active molecular lipid species, such as PC(16:0/2:0), 9 that may impact platelet activation.
At first glance, the difference in the final selection of molecular lipid species is apparent, also with regard to previous lipidomics studies on cardiometabolic disease. [10] [11] [12] [13] [14] [15] This is not unexpected given the sources of variability in lipidomics measurements (Figure) . However, there are also consistencies.
A number of studies targeting CVD and diabetes mellitus unraveled associations with cholesteryl esters (CEs), 13, 15 predominantly of species with shorter-chain and more saturated fatty acids, such as CE(16:0) and CE(16:1). The relevance of CE is expected to decline with statin therapy. About 40% of the diabetic patients evaluated by Alshehry et al 8 received lipid-lowering medication. Yet, CE(16:0) still emerged as significantly associated with incident CVD, and CE(18:0) was in their final selection.
Triacylglycerols (TGs) were part of adverse lipid signatures identified previously. [12] [13] [14] [15] Alshehry et al 8 detected a signal of protection for TG(56:6), but no TG species were in their final selection. Potential reasons for this discrepancy are the limited variability of TG levels in diabetic dyslipidemia, the use of lipid-lowering medication including fibrates, lifestyle-modifying strategies including diet, and the single-phase extraction procedure applied in this and another study, which failed to obtain an association for TG. 8, 12 Single-phase extraction methods may result in less efficient extraction of TG. 5 Lyso-PCs relate to the risk of CVD, diabetes mellitus, and other metabolic abnormalities in most studies available so far, including those published in the current issue of Circulation, 7, 8 but the selected molecular species and their directionality differ. It remains to be defined whether this reflects biological variation as suggested 8, 9 or arises from methodological differences in the measurements.
The perhaps most consistent finding in the published lipidomic studies so far is a general shift in fatty acid chain length across multiple lipid classes in men and women. Species with shorter or more saturated fatty acid substituents confer risk, whereas species possessing longer or polyunsaturated fatty acids offer protection. 8, 13 This is corroborated by a large metabolic profiling study using nuclear magnetic resonance spectroscopy, an entirely different technological platform from MS: plasma monounsaturated fatty acids (which are generated from saturated fatty acids by the action of stearoyl coenzyme A desaturase-1), were again directly associated with incident CVD, whereas polyunsaturated fatty acids showed an inverse association. 16 This is in line with previous research on dietary fatty acids and CVD. 17 It also implicates a role for hepatic de novo lipogenesis, the endogenous synthesis of fatty acids from glucose and fructose, which is influenced by lifestyle and diet. Hepatic de novo lipogenesis produces mostly saturated fatty acids with 16 to 18 carbon atoms and, at most, a single double bond. Therapeutic inhibitors of de novo lipogenesis have been developed and studied in obesity.
A necessary next step toward clinical application of lipidomics is the standardization of the measurement methods. Lipidomics has potential in the context of cardiometabolic disease, but requires methodological standardization and better interlaboratory reproducibility before its power can be harnessed toward clinical application. Another important consideration is that most plasma lipids are associated with apolipoproteins, and thus associations of lipid species with CVD may partly reflect associations of apolipoproteins with CVD. Apart from apolipoprotein A1 and apolipoprotein B, other apolipoproteins have not been extensively explored in the context of lipidomics measurements to date. It will be interesting to see which of the 2 postgenomic technologies, lipidomics or proteomics, will deliver new biomarkers with clinical utility for CVD. 18, 19 
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